- Home
- RIGL vs AEVA Comparison
RIGL vs AEVA Comparison
Compare RIGL & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | AEVA |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 600.2M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | AEVA |
|---|---|---|
| Price | $44.01 | $13.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $43.20 | $26.50 |
| AVG Volume (30 Days) | 506.3K | ★ 2.0M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | ★ $282,076,000.00 | $15,154,000.00 |
| Revenue This Year | $65.53 | $87.44 |
| Revenue Next Year | $0.22 | $70.13 |
| P/E Ratio | $7.10 | ★ N/A |
| Revenue Growth | 79.13 | ★ 89.90 |
| 52 Week Low | $15.50 | $2.52 |
| 52 Week High | $52.24 | $38.80 |
Technical Indicators
Market Signals| Indicator | RIGL | AEVA |
|---|---|---|
| Relative Strength Index (RSI) | 53.60 | 47.29 |
| Support Level | $40.52 | $12.83 |
| Resistance Level | $44.85 | $15.73 |
| Average True Range (ATR) | 2.33 | 1.24 |
| MACD | -0.27 | -0.11 |
| Stochastic Oscillator | 51.26 | 7.33 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.